PMID: 8943101Dec 1, 1996Paper

Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)

Journal of Neuro-oncology
J GlassM L Gruber

Abstract

Prior studies have suggested that pre-irradiation methotrexate (MTX)-based chemotherapy improves duration of response and survival in primary central nervous system lymphoma (PCNSL). To circumvent the potential emergence of drug resistance, we combined high-dose MTX with agents highly active against systemic lymphoma. Patients received three week cycles of CHOD (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1.4 mg/m2 [2 mg maximum] on day 1; dexamethasone 10 mg/m2 days 1-5), and MTX (3.5 gm/m2) with leucovorin rescue on day 8 (or on recovery from the CHOD nadir). Whole brain irradiation (WBRT) was planned after at least three cycles. Eighteen patients were treated. Complete responses were seen in eleven patients, and partial responses in three. Four progressed during therapy, three succumbing to progressive disease and one subsequently responding to WBRT. Response duration was 37.5 months in those responding to therapy. The time to progression for all eighteen patients was 19.5 months. Medial survival was 25.5 months. Disease-free survival was 50% at 38 months in MCHOD responders. Grade 3 or 4 myelotoxicity was seen in 19 of 50 cycles. There were three instances of neutropenic fever, three of azotemia, two o...Continue Reading

Citations

May 16, 2006·Journal of Neuro-oncology·Kristoph JahnkeUNKNOWN German Primary Central Nervous System Lymphoma Study Group
Feb 1, 2003·Lancet·Anthony BehinJean-Yves Delattre
May 31, 2001·International Journal of Radiation Oncology, Biology, Physics·E M BessellP Byrne
Jul 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·U Basso, A A Brandes
Mar 22, 2002·The Lancet Oncology·S R Plotkin, T T Batchelor
May 1, 2010·Expert Opinion on Pharmacotherapy·Matteo G CarrabbaAndrés J M Ferreri
Jul 17, 2012·Hematology/oncology Clinics of North America·Priscilla K Brastianos, Tracy T Batchelor
Mar 14, 2012·Best Practice & Research. Clinical Haematology·Andrés J M Ferreri, Emerenziana Marturano
Nov 15, 2001·Clinical Lymphoma·S R Plotkin, T T Batchelor
Jul 15, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michele ReniAndrés J M Ferreri
Apr 14, 2016·British Journal of Haematology·Jessica HochbergOussama Abla
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E M BessellFrancesc Graus
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy BatchelorRegina Priet
Jun 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrés J M FerreriTracy Batchelor
Feb 24, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B KasendaM Briel
Feb 23, 1999·British Journal of Cancer·M ReniE Villa
Oct 17, 2009·Expert Review of Neurotherapeutics·Kristoph Jahnke, Eckhard Thiel
May 19, 2012·Expert Review of Anticancer Therapy·Patrick RothMichael Weller
May 27, 2011·Blood·Andrés J M Ferreri
May 13, 2009·The Oncologist·Monica Sierra del RioKhê Hoang-Xuan

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.